In a recent issue of Bone Marrow Transplant, Nordoy et al 1 described the declining protective immunity against poliomyelitis in their 35 patients with malignant lymphoma in CR 4-10 years after ABMT. Currently, wild polioviruses are not much in evidence, and even the live vaccines are not being used universally. Global eradication of poliomyelitis is not all that far off. Undoubtedly, it is essential to address the declining poliomyelitis immunity among lymphoma patients who are currently being meticulously offered vaccines according to EBMT guidelines.
A decline in vaccine-induced protective immunity has been associated with both live and inactivated vaccine. The waning of the antibody level with live polio vaccine is directly related to the time when the last dose of vaccine was given and not to the number of doses administered. 2 After the termination of the live vaccine era in Germany and the change to inactivated vaccine, the prevalence of type 3 antibody declined from 78% in 1990-1992 to 68% in 1997. Among children aged 5-14 years, the decline was from 74% in 1990 to 47% in 1997. 3 Lymphoma patients receiving ABMT should be periodically evaluated for their antibody levels to all the three types of polioviruses. All those who lack antibody to any poliovirus serotype should be immunized. Ideally, they should be monitored for their post-vaccination serological response. Diminished or negligible immunity against poliomyelitis in such subjects domiciled in otherwise poliomyelitis-free countries constitutes to be a threat for the individual as well as the community. In the event of any unexpected dissemination of an imported or indigenous poliovirus strain in a poliomyelitis-free area, episodes of poliomyelitis occur even among adolescents and young adults. During the recent poliomyelitis outbreak in Bulgaria, apart from infants, there were episodes of acute flaccid paralysis in those in the second or third decade of their life. 4 Furthermore, two healthy British tourists, aged 62 and 65 years, were afflicted with poliomyelitis during their holiday in a beach resort in Morocco. 5 Potentially neurovirulent polioviruses are frequent in raw sewage and river water in poliomyelitis-free industrialized countries. 6 In all probability, such strains do not pose much danger to the residents in poliomyelitis-free areas. Nevertheless, incessant torrential rains, unrelenting flooding of river waters or natural disasters could produce a paucity of safe drinking water and/or exposure to infected water. This would expose lymphoma patients who have undergone ABMT and who lack poliomyelitis immunity 1 to a serious risk of acute flaccid paralysis.
Last but not least, following any replication of polioviruses in intestines, there could be dissemination of the excreted poliovirus in the household or community of lymphoma patients after ABMT. Such an eventuality could be avoided by frequent monitoring of their poliomyelitis immunity. However, quantification of poliovirus antibody is a multistep procedure which is not undertaken by many laboratories. The additional expenditure on external assistance towards poliovirus surveillance would be cost effective in avoiding poliovirus replication and dissemination in a poliomyelitis-susceptible malignant lymphoma patient after ABMT.
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